ACHE and Alzheimer disease: Interestingly, MD simulations of a survey of tacrine-huprine heterodimers revealed that derivatives show potential for AD and prion disease treatment because they both inhibit the PAS and CAS in AChE while reducing β-amyloid and prion peptide aggregation [96].